|
|
PredicTOR: predicting patient response to mTOR pathway inhibitors prior to treatm
|
5R44CA123994-06
|
$980,392
|
$323,529
|
GILLESPIE, JOHN
|
20/20 GENESYSTEMS, INC.
|
|
|
Humanization of a mouse anti-OX40 monoclonal antibody to treat cancer
|
1R43CA159797-01A1
|
$187,201
|
$93,601
|
Triglia, Dennis
|
AGONOX, INC.
|
|
|
EASTERN COOPERATIVE ONCOLOGY GROUP
|
5U10CA014958-38
|
$101,749
|
$1,017
|
Sparano, Joseph
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Radiation Therapy Oncology Group
|
3U10CA021661-36S1
|
$172,284
|
$1,723
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Radiation Therapy Oncology Group
|
5U10CA021661-36
|
$12,915,055
|
$129,151
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Bay Area Tumor Institute CCOP
|
2U10CA045461-23
|
$486,165
|
$14,585
|
FEUSNER, JAMES
|
BAY AREA TUMOR INSTITUTE
|
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-28
|
$607,994
|
$6,080
|
Nichols, Craig
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
|
Mechanism of Acquired Resistance to VEGF-R Antagonists in RCC
|
5K08CA138900-03
|
$169,560
|
$169,560
|
BHATT, RUPAL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Eastern Cooperative Oncology Group
|
5U10CA080775-14
|
$95,411
|
$954
|
BUBLEY, GLENN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Targeting the PI3-Kinase/Akt Pathway for the Therapy of Renal Cell Carcinoma
|
5K08CA142890-04
|
$169,400
|
$169,400
|
Cho, Daniel
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-09
|
$2,300,000
|
$2,300,000
|
McDermott, David
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Pathway Specific Imaging in VHL Deficient Renal Cancer
|
5R01CA152330-02
|
$355,534
|
$355,534
|
SETH, PANKAJ
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
The pVHL/Jade-1/beta-catenin axis in renal cancer
|
3R01CA079830-11S1
|
$22,311
|
$22,311
|
COHEN, HERBERT
|
BOSTON MEDICAL CENTER
|
|
|
The pVHL/Jade-1/beta-catenin axis in renal cancer
|
5R01CA079830-11
|
$320,196
|
$320,196
|
COHEN, HERBERT
|
BOSTON MEDICAL CENTER
|
|
|
VHL tumor suppressor gene and the initiation of renal cell carcinoma
|
3R01CA109860-08S1
|
$75,516
|
$75,516
|
HSU, TIEN
|
BOSTON MEDICAL CENTER
|
|
|
VHL tumor suppressor gene and the initiation of renal cell carcinoma
|
5R01CA109860-08
|
$328,499
|
$328,499
|
HSU, TIEN
|
BOSTON MEDICAL CENTER
|
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S1
|
$300,000
|
$6,000
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S2
|
$139,989
|
$2,800
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
|
The MB-CCOP at Boston Medical Center
|
5U10CA139519-03
|
$310,336
|
$6,207
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
|
Cancer and Leukemia Group B
|
3U10CA031946-31S1
|
$114,228
|
$3,427
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Cancer and Leukemia Group B CCOP Research Base
|
3U10CA037447-27S1
|
$405,901
|
$4,059
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Cancer and Leukemia Group B
|
5U10CA031946-31
|
$7,759,618
|
$232,789
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Cancer and Leukemia Group B CCOP Research Base
|
5U10CA037447-28
|
$2,286,202
|
$22,862
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Molecular Pathogenesis of the Hamartoma Syndromes
|
2P01CA120964-06A1
|
$1,911,547
|
$152,924
|
KWIATKOWSKI, DAVID
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Computerized Monitoring Tool for MR-Guided Cryoablation
|
5R01CA152282-03
|
$523,432
|
$523,432
|
Tuncali, Kemal
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
To establish the BC Cancer Agency - Vancouver Centre as a major SWOG centre
|
5U10CA142559-03
|
$131,854
|
$9,230
|
BLANKE, CHARLES
|
BRITISH COLUMBIA CANCER AGENCY
|
|
|
Proteo-genomic Discovery, Prioritization and Verification of Cancer Biomarkers
|
5U24CA160034-02
|
$3,122,514
|
$780,629
|
CARR, STEVEN
|
BROAD INSTITUTE, INC.
|
|
|
Engineering Triggered Nanomechanical Therapeutics
|
5R01CA140759-04
|
$322,899
|
$113,015
|
PIERCE, NILES
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
|
Eastern Cooperative Oncology Group Studies
|
5U10CA014548-38
|
$354,850
|
$3,549
|
AVERBOOK, BRUCE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-22S3
|
$4,849,180
|
$145,475
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-22S4
|
$74,396
|
$2,232
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Staging of upper tract urothelial cancer with optical coherence tomography
|
1R21CA165398-01
|
$304,012
|
$304,012
|
ROLLINS, ANDREW
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Cedar Rapids Oncology Project
|
5U10CA052352-23
|
$326,434
|
$6,529
|
Wilbur, Deborah
|
CEDAR RAPIDS ONCOLOGY PROJECT
|
|
|
Expression profiling of renal cell carcinoma utilizing tissue from CALGB 90206
|
5R01CA133072-06
|
$343,754
|
$343,754
|
KIM, HYUNG
|
CEDARS-SINAI MEDICAL CENTER
|
|
|
Cadherin-regulated apoptosis and survival signaling in epithelial cells
|
5R01CA142647-02
|
$361,050
|
$361,050
|
HANSEN, STEEN
|
CHILDREN'S HOSPITAL BOSTON
|
|
|
Pathophysiology of Post-Transplantation Cancer
|
5R01CA131145-04
|
$350,219
|
$350,219
|
Pal, Soumitro
|
CHILDREN'S HOSPITAL BOSTON
|
|
|
Children's Oncology Group Chair's Grant
|
3U10CA098543-10S3
|
$176,626
|
$21,195
|
ADAMSON, PETER
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
|
Children's Oncology Group Chair's Grant
|
7U10CA098543-10
|
$26,733,729
|
$3,208,047
|
ADAMSON, PETER
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
|
Genetics of pediatric rhabdoid tumors
|
5R01CA046274-21
|
$258,854
|
$88,010
|
BIEGEL, JACLYN
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
|
Community Clinical Oncology Program Research Base
|
2U10CA095861-11
|
$1,608,610
|
$193,033
|
POLLOCK, BRAD
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
|
Delaware/Christiana Care Community Clinical Oncology Program
|
2U10CA045418-26
|
$1,423,934
|
$28,479
|
GRUBBS, STEPHEN
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
|
City of Hope Southwest Oncology Group Clinical Trials
|
5U10CA046368-25
|
$340,319
|
$23,822
|
MORTIMER, JOANNE
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
Sunitinib Modulation of Cancer Immunotherapy
|
5R01CA150959-03
|
$528,446
|
$528,446
|
FINKE, JAMES
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
|
Investigation of HIF-dependent and -independent tumor suppressor functions of VHL
|
1R01CA155015-01A1
|
$325,775
|
$325,775
|
Yang, Haifeng
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
|
Columbia University Medical Center Minority-Based Community Clinical Oncology Pro
|
1U10CA167791-01
|
$796,302
|
$23,889
|
GRANN, VICTOR
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Columbus Community Clinical Oncology Program (Columbus CCOP)
|
5U10CA035261-29
|
$813,151
|
$8,132
|
KUEBLER, J
|
COLUMBUS COMMUNITY CLINICAL ONCOLOGY PRG
|
|
|
Cancer Center Support Grant
|
2P30CA006516-47
|
$11,164,583
|
$223,292
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Cancer Center Support Grant
|
3P30CA006516-47S1
|
$56,572
|
$1,131
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Cancer Center Support Grant
|
3P30CA006516-47S2
|
$75,000
|
$1,500
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Cancer Center Support Grant
|
3P30CA006516-47S3
|
$50,000
|
$1,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
Total relevant funding to Kidney Disease for this search: $51,591,343
|
